Clinical trial · Observational
Amino Acid PET to Assess the Efficacy of IDH Inhibitor Treatments for IDH Mutated Gliomas
Amino Acid PET Imaging to Assess the Efficacy of IDH Inhibitor Treatments for Patients With Refractory IDH Mutated Gliomas
NCT07017790CI-TRIAL-00115823TEP-IDHcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Amino acid PET imaging could represent a biomarker for the evaluation of IDH inhibitor treatments for patients with refractory IDH-mutated gliomas
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioma | Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Amino-acid PET | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Compare the performance between amino acid PET and brain MRI to assess a treatment efficacy
- timeFrame
- one day
- description
- Comparison between early therapeutic response according to RANO 1.0 and RANO 2.0 PET criteria and tumor progression at 6 months
Secondary outcomes (1)
- measure
- Compare the performance between amino acid PET and brain MRI to assess a treatment efficacy for the identification of lesions
- timeFrame
- one day
- description
- Determination of the number of lesions assessable by amino acid PET according to RANO 1.0 PET criteria and by MRI according to RANO 2.0 criteria
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who underwent amino acid PET for early assessment of therapeutic response of IDH-mutated gliomas under anti-IDH treatment between February 2022 and November 2024 Exclusion Criteria: * Individuals who have objected to the use of their data
References
Publications (1)
- RESULTStien G, Obara T, Truong M, Zaragori T, Blonski M, Taillandier L, Verger A. Amino acid PET imaging to monitor mIDH inhibitor treatments in patients with refractory IDH-mutant gliomas. Eur J Nucl Med Mol Imaging. 2026 Jul;53(8):5101-5109. doi: 10.1007/s00259-026-07895-2. Epub 2026 Apr 17. PMID 41995839